Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tenax Therapeutics (TENX) EBITDA Margin: 2010-2016

Historic EBITDA Margin for Tenax Therapeutics (TENX) over the last 2 years, with Dec 2016 value amounting to 2,228,869.01%.

  • Tenax Therapeutics' EBITDA Margin was N/A to 2,228,869.01% in Q4 2016 from the same period last year, while for Dec 2016 it was 1,643.20%, marking a year-over-year change of. This contributed to the annual value of 84,756.52% for FY2024, which is 11688433.00% up from last year.
  • Per Tenax Therapeutics' latest filing, its EBITDA Margin stood at 2,228,869.01% for Q4 2016, which was up 1,020.40% from -242,161.79% recorded in Q2 2015.
  • In the past 5 years, Tenax Therapeutics' EBITDA Margin ranged from a high of 2,228,869.01% in Q4 2016 and a low of -242,161.79% during Q2 2015.
  • For the 2-year period, Tenax Therapeutics' EBITDA Margin averaged around 993,353.61%, with its median value being 993,353.61% (2015).
  • Data for Tenax Therapeutics' EBITDA Margin shows a peak YoY increase of 914,614bps (in 2012) and a maximum YoY decrease of 1,162,433bps (in 2012) over the last 5 years.
  • Tenax Therapeutics' EBITDA Margin (Quarterly) stood at -132.62% in 2012, then slumped by 249,266bps to -4,444.87% in 2013, then reached -242,161.79% in 2015, then reached 2,228,869.01% in 2016.
  • Its EBITDA Margin stands at 2,228,869.01% for Q4 2016, versus -242,161.79% for Q2 2015 and -4,444.87% for Q2 2013.